2344. FDA Analysis of CD4(+) Cell Count Declines Observed in HIV-Infected Children Treated With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide

BACKGROUND: Elvitegravir (EVG)/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is approved for treatment of HIV-1 in children weighing ≥25 kg based on a Gilead sponsored study of safety, pharmacokinetics (PK), and antiviral activity among 23 virologically suppressed (VS) children 6–<12...

Descripción completa

Detalles Bibliográficos
Autores principales: Bell, Tanvir, Baylor, Melisse, Rhee, Sung, Tracy, LaRee, Sampson, Mario, Younis, Islam, Belew, Yodit, Carter, Wendy, Viswanathan, Prabha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253452/
http://dx.doi.org/10.1093/ofid/ofy210.1997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6253452/
http://dx.doi.org/10.1093/ofid/ofy210.1997

Ejemplares similares